[Treatment of haemophilia in Austria].
Hämophilie-Behandlung in Österreich.
Antifibrinolytics
Clotting Factor Concentrates
Desmopressin
Guideline
Haemophilia
Inhibitors
Non-Replacement Therapies
Outcomes
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
accepted:
17
04
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
ppublish
Résumé
This guideline is intended to provide practical guidance for the diagnosis and treatment of haemophilia in Austria. Few randomized controlled interventional trials are available addressing the treatment of haemophilia, therefore recommendations are usually based on low level of evidence and represent expert consensus.This guideline is based on the WFH guideline, published in 2020, and adapted according to the national circumstances and experience.It includes recommendations and suggestions for diagnosis and follow-up visits and pharmacological therapies for treatment and prophylaxis. Further topics comprise special aspects in children and adults with severe haemophilia, outcome measurement, and management of trauma, special bleedings and interventions, including dental procedures, inhibitors, management of haemophilia carriers, and psychosocial aspects. Die vorliegende aktualisierte Leitlinie soll einen praxisnahen Leitfaden für die Diagnostik und Therapie von Personen mit Hämophilie (Persons with Haemophilia, PwH) in Österreich darstellen. In der Hämophilie-Therapie gibt es wenige vergleichende Interventionsstudien, daher haben die Empfehlungen einen meist niedrigen Evidenzgrad und beruhen auf einem Expertenkonsensus.Als wesentliche Grundlage dieser Leitlinie dienen die internationalen Guidelines der „World Federation of Hemophilia (WFH)“ aus dem Jahr 2020. Diese wurden den nationalen Gegebenheiten und Erfahrungen angepasst.Behandelt werden Diagnostik und Verlaufskontrollen, medikamentöse sowie begleitende Therapieoptionen und Prophylaxe, weiters spezielle Aspekte bei Kindern und Erwachsenen mit schwerer Hämophilie, Messung von Outcomes, die Vorgehensweise bei Traumen, speziellen Blutungen und Eingriffen einschließlich Zahnextraktionen, das Thema Hemmkörper sowie mögliche Probleme bei Konduktorinnen und psychosoziale Aspekte bei Hämophilie.
Autres résumés
Type: Publisher
(ger)
Die vorliegende aktualisierte Leitlinie soll einen praxisnahen Leitfaden für die Diagnostik und Therapie von Personen mit Hämophilie (Persons with Haemophilia, PwH) in Österreich darstellen. In der Hämophilie-Therapie gibt es wenige vergleichende Interventionsstudien, daher haben die Empfehlungen einen meist niedrigen Evidenzgrad und beruhen auf einem Expertenkonsensus.Als wesentliche Grundlage dieser Leitlinie dienen die internationalen Guidelines der „World Federation of Hemophilia (WFH)“ aus dem Jahr 2020. Diese wurden den nationalen Gegebenheiten und Erfahrungen angepasst.Behandelt werden Diagnostik und Verlaufskontrollen, medikamentöse sowie begleitende Therapieoptionen und Prophylaxe, weiters spezielle Aspekte bei Kindern und Erwachsenen mit schwerer Hämophilie, Messung von Outcomes, die Vorgehensweise bei Traumen, speziellen Blutungen und Eingriffen einschließlich Zahnextraktionen, das Thema Hemmkörper sowie mögliche Probleme bei Konduktorinnen und psychosoziale Aspekte bei Hämophilie.
Identifiants
pubmed: 38743098
doi: 10.1007/s00508-024-02370-0
pii: 10.1007/s00508-024-02370-0
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
75-102Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Pabinger I, Heistinger M, Muntean W, Reitter-Pfoertner SE, Rosenlechner S, Schindl T, Schuster G, Streif W, Thom K, Male C. Hämophiliebehandlung in Österreich. Wien Klin Wochenschr 2015;127[Suppl 3]:115–130. https://doi.org/10.1007/s00508-015-0872-x .
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26:1–158.
pubmed: 32744769
doi: 10.1111/hae.14046
WFH. Report on the Annual Global Survey. 2022. https://elearning.wfh.org/resource/report-on-the-annual-global-survey-2022/ .
Schulman S. Mild Hemophilia—Revised. Edition. 2012;(41). 2012 [2014/09/09]; Available from: http://www.wfh.org/en/page.aspx?pid=1270 .
University College London. Factor VIII Variant Database. [2024-01-31]; Available from: http://www.factorviii-db.org/ .
Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia. 2008;14(2):361–74.
pubmed: 18248408
doi: 10.1111/j.1365-2516.2007.01625.x
Endler G, Slavka G, Perkmann T, Haushofer A. [The importance of preanalytics for the coagulation laboratory]. Hämostaseologie. 2010;30(2):63–70. Epub 2010/05/11. Die Bedeutung der Praanalytik fur das Gerinnungslabor.
Knöbl P, Erworbene Hemmkörper-Hämophilie SM. Ligatur-Verlag. 2009. ISBN 978-3-940407-19‑1.
Wissenschaftlicher Beirat der Österreichischen Hämophilie Gesellschaft. Konsensus über die Verwendung von Faktorenkonzentraten bei Patienten mit Hämophilie (Version v. Nov. 2020). Available from: https://bluter.at/wp/wp-content/uploads/2021/02/Konsensus-des-Wissenschaftlichen-Beirates-zur-Therapie-der-Haemophilie.pdf
Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308.
pubmed: 30210757
pmcid: 6130100
doi: 10.1177/2040620718796429
Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397:630–40.
pubmed: 33460559
doi: 10.1016/S0140-6736(20)32722-7
Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487–98.
pubmed: 27311929
doi: 10.1111/hae.13013
Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
pubmed: 22776238
doi: 10.1111/j.1365-2516.2012.02909.x
Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1‑4 studies. Blood 2021 Apr 22;137(16):2231–2242. https://doi.org/10.1182/blood.2020009217
Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024;143:1355–1364.
Swan D, Mahlangu J, Thachil J. Non-factor therapies for bleeding disorders: A primer for the general haematologist. EJHaem. 2022;3:584–95.
pubmed: 36051064
pmcid: 9422036
doi: 10.1002/jha2.442
Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–25.
pubmed: 35294811
doi: 10.1056/NEJMoa2113708
Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388(8):694–705.
pubmed: 36812433
doi: 10.1056/NEJMoa2211075
Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706–18.
pubmed: 36812434
doi: 10.1056/NEJMoa2211644
Coppens M, Pipe SW, Miesbach W, et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.; HOPE-B Investigators. Lancet Haematol. 2024 Apr;11(4):e265-e275.
Miesbach W, Chowdary P, Coppens M, et al. Delivery of AAV-based gene therapy through haemophilia centres—A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia. 2021 Nov;27(6):967–973. https://doi.org/10.1111/hae.14420 . Epub 2021 Sep 22.
Miesbach W, Oldenburg J, Klamroth R, et al. Gene therapy of Hemophilia: Recommendations from the German, Austrian, and Swiss Society for Thrombosis and Haemostasis Research (GTH). Haemostaseologie. 2023;43(3):196–207. https://doi.org/10.1055/a-1957-4477 .
doi: 10.1055/a-1957-4477
AWMF-Leitlinie „Therapie angeborener thrombozytärer Erkrankungen“, AWMF-Register Nr. 086-004, Klasse: S2K, erhältlich unter http://www.awmf.org/leitlinien/detail/ll/086-004.html . Accessed 2024-01-31.
Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14(4:671–84.
doi: 10.1111/j.1365-2516.2008.01695.x
Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339(4):245–53.
pubmed: 9673304
doi: 10.1056/NEJM199807233390407
van Galen KP, Engelen ET, Mauser-Bunschoten EP, et al. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev. 2019 Apr 19;4(4):CD011385. https://doi.org/10.1002/14651858.CD011385.pub3
Ullah K, Mukhtar H, Khalid U, et al. Is Antifibrinolytic Therapy Effective for Preventing Hemorrhage in Patients with Hemophilia Undergoing Dental Extractions? A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221114862. https://doi.org/10.1177/10760296221114862 .
Giangrande PL, Wilde JT, Madan B, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009;15(2:501–8.
doi: 10.1111/j.1365-2516.2008.01952.x
Richards M, Williams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149(4):498–507.
pubmed: 20230411
doi: 10.1111/j.1365-2141.2010.08139.x
Ljung R, Fischer K, Carcao M, al group INPH. Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thromb Haemost. 2016;115:913–20.
pubmed: 26791493
doi: 10.1160/TH15-08-0664
Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia. 2002;8(6):745–52.
pubmed: 12410642
doi: 10.1046/j.1365-2516.2002.00695.x
S2k-Leitlinie Synovitis bei Hämophilie. Version 2.0. Stand 15. Jan. 2022. AWMF-Registernummer: 086-005. Abrufbar unter: http://www.awmf.org/leitlinien/detail/ll/086-005.html . Accessed 2024-01-31.
Stromer W, Pabinger I, Ay C, et al. Pain management in hemophilia: expert recommendations. WKWO 2021;133(19–20):1042–1056.
Stromer W, Messerer B, Crevenna R, et al. Schmerztherapie bei Kindern und Jugendlichen mit Hämophilie. Handlungsempfehlungen einer Expertengruppe. Schmerz. 2018;32:404–18.
pubmed: 30191308
doi: 10.1007/s00482-018-0321-7
Taddio A, Ohlsson A, Einarson TR, et al. A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. Pediatrics. 1998;101(2):E1. https://doi.org/10.1542/peds.101.2.e1 .
doi: 10.1542/peds.101.2.e1
pubmed: 9445511
World Federation of Hemophilia (WFH). Compendium of assessment tools. [2013/10/01]; Available from: http://www.wfh.org/en/page.aspx?pid=882 .
Gringeri A, Von Mackensen S. Quality of life in haemophilia. Haemophilia. 2008;14([Suppl3):19–25.
pubmed: 18510517
doi: 10.1111/j.1365-2516.2008.01709.x
Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: Defining patient important outcomes. Res Pract Thromb Haemost. 2019;3(2):184–92.
pubmed: 31011702
pmcid: 6462740
doi: 10.1002/rth2.12195
Fischer K, de Kleij P, Negrier C, et al. The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis. Haemophilia. 2016;22(6):833–40.
pubmed: 27785891
doi: 10.1111/hae.13120
Njidam A, Foppen W, van der Schouw YT, et al. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia. 2016;22:852–8.
doi: 10.1111/hae.12959
Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–44.
pubmed: 17687129
doi: 10.1056/NEJMoa067659
Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16(2):256–62. Mar.
pubmed: 19878331
doi: 10.1111/j.1365-2516.2009.02122.x
Auerswald G, Kurnik K, Aledort LM, et al. EPIC clinical study group. The EPIC study: a lesson to learn. Haemophilia. 2015;21(5):622–8. Sep.
pubmed: 25912619
doi: 10.1111/hae.12666
Gouw SC, van der Bom JG, van den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;1;109(11):4648–54. Jun.
pubmed: 17289808
doi: 10.1182/blood-2006-11-056291
Pipe SW, Collins PW, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood. 2023 Dec 21:blood.2023021832. https://doi.org/10.1182/blood.2023021832 .
Mancuso ME, Male C, Kenet G, et al. Prophylaxis in children with haemophilia in an evolving treatment landscape. Haemophilia. 2021; https://doi.org/10.1111/hae.14412 .
doi: 10.1111/hae.14412
pubmed: 34727394
pmcid: 9290859
Carpenter SL, Soucie JM, Presley RJ, et al. Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis. Haemophilia. 2015;21(1):e39–43.
pubmed: 25381731
doi: 10.1111/hae.12569
Kroger AT, Atkinson WL, Pickering LK. 8—General immunization practices. In: Offit PA, Plotkin SA, Orenstein WA, editors. Vaccines (Sixth Edition). London: W.B. Saunders; 2013. p. 88–112.
Injektionsweg mit Fokus Injektion bei Blutungsneigung. https://www.rki.de/DE/Content/Infekt/Impfen/Stichwortliste/G/Injektionsort_Tabelle.pdf . Accessed 2024-01-31.
Tiede A, Leise H, Horneff S, et al. Safety of intramuscular COVID-19 vaccination in patients with haemophilia. Haemophilia. 2022;28(5):687–93. Sep.
pubmed: 35561276
doi: 10.1111/hae.14586
Pfrepper C, Holstein K, Königs C, et al. Hemophilia Board of the German, Austrian, Swiss Society on Thrombosis Hemostasis Research (GTH). Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia. Hamostaseologie. 2021;41(3):190–6. Jun.
pubmed: 33860513
doi: 10.1055/a-1401-2691
Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia. 2004;10:134–46.
pubmed: 14962202
doi: 10.1046/j.1365-2516.2003.00840.x
Thom KE, Hoelzenbein T, Jones N, et al. Arterio-venous shunts as venous access in children with haemophilia. Haemophilia. 2018;24:429–35.
pubmed: 29573510
doi: 10.1111/hae.13433
Breakey VR, Ignas DM, Warias AV, et al. A pilot randomized control trial to evaluate the feasibility of an Internet-based self-management and transitional care program for youth with haemophilia. Haemophilia. 2014;20(6):784–93.
pubmed: 25311370
doi: 10.1111/hae.12488
Mortensen LG, Strand AM, Almen L. Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: a qualitative review. Haemophilia. 2018;24(6):862–72.
doi: 10.1111/hae.13621
Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia. 2009;15(5):1014–21.
pubmed: 19493018
doi: 10.1111/j.1365-2516.2009.02036.x
Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal Thromb Haemost 2017;15(11):2115–2124.
Nijdam A, Foppen W, De Kleijn P, et al. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thromb Haemost. 2016;115(5):931–8.
pubmed: 26791021
doi: 10.1160/TH15-08-0637
Holstein K, Batorova A, Carvalho M, et al. Current view and outcome of ITI therapy—A change over time? Thromb Res. 2016;148:38–44.
pubmed: 27770665
doi: 10.1016/j.thromres.2016.10.015
Khair K, Chalmers E, Flannery T, et al. Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study. Ther Adv Hematol. 2021;12:20406207211007058.
pubmed: 33995986
pmcid: 8111519
doi: 10.1177/20406207211007058
Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. Eur J Haematol. 2003;70(6):410–2.
pubmed: 12756025
doi: 10.1034/j.1600-0609.2003.00077.x
Singleton T, Kruse-Jarres R, Leissinger C. Emergency department care for patients with hemophilia and von Willebrand disease. J Emerg Med. 2010;39(2):158–65.
pubmed: 18757163
doi: 10.1016/j.jemermed.2007.12.024
Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–9. Nov.
pubmed: 25059285
doi: 10.1111/jth.12672
Bajkin B, Dougall A. Current state of play regarding dental extractions in patients with haemophilia: Consensus or evidence-based practice? A review of the literature. Haemophilia. 2020;26(2):183–99. Mar.
pubmed: 31962377
doi: 10.1111/hae.13928
Mancuso ME, Apte S, Hermans C. Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022. Haemophilia. 2022;28(S4):93–102.
pubmed: 35521735
doi: 10.1111/hae.14551
van den Berg HM, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019;134:317–20.
pubmed: 31186271
doi: 10.1182/blood.2019000658
Male C, Gretenkort N, Rafowicz A, et al. on behalf of the PedNet study group. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2021;106:123–9.
pubmed: 31919092
doi: 10.3324/haematol.2019.239160
van Velzen AS, Eckhardt CL, Peters M, et al. Intensity of factor VIII treatment and the development of inhibitors in non-severe in non-severe hemophilia A patients: results of the INSIGHT case-control study. J Thromb Haemost. 2017;15:1422–9.
pubmed: 28440011
doi: 10.1111/jth.13711
Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost. 2009;35(8):752–9.
pubmed: 20169511
doi: 10.1055/s-0029-1245107
Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546–51.
pubmed: 16990605
doi: 10.1182/blood-2006-04-017988
Rangarajan S, Austin S, Goddard NJ, et al. Consensus recommendations for the use of FEIBA
doi: 10.1111/hae.12028
Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa (NovoSeven
doi: 10.1111/j.1365-2516.2010.02460.x
Fachinformation NovoSeven. https://www.ema.europa.eu/en/documents/product-information/novoseven-epar-product-information_en.pdf .
Fachinformation FEIBA. https://www.takeda-produkte.de/system/files/produkt-info/fachinformation-feiba-nf-500-e1000-e-pulver-und-losungsmittel-zur-herstellung-einer-injektionslosung.pdf .
Fachinformation Cevenfacta. https://www.ema.europa.eu/en/documents/product-information/cevenfacta-epar-product-information_en.pdf .
Collins P, Chalmers E, Alamelu J, et al. First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors’ Organisation Inhibitor and Paediatric Working Parties. Haemophilia. 2017;23(5):654–9. Sep.
pubmed: 28574205
doi: 10.1111/hae.13264
Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335–44.
Batsuli G, Zimowski KL, Tickle K, et al. Epub 2019 Aug 2. Haemophilia. 2019;25(5):789–96.
pubmed: 31373431
doi: 10.1111/hae.13819
Holstein K, Albisetti M, Bidlingmaier C, et al. on behalf of the ‘Ständige Kommission Hämophilie’ (Haemophilia board) of the German, Austrian, Swiss Society for Thrombosis Haemostasis Research (GTH). Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A. Haemostaseologie 2020;40:561-571.
Streif W, Knöfler R. Perinatal Management of Haemophilia. Haemostaseologie. 2020;40:226–32.
https://www.gesundheit.gv.at/leben/eltern/schwangerschaft/info/schwangerschaftsabbruch . (accessed 2024-01-31)